![Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma](https://www.frontiersin.org/files/Articles/454940/fonc-09-00537-HTML/image_m/fonc-09-00537-g001.jpg)
Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
![Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications - Cancer Treatment Reviews Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications - Cancer Treatment Reviews](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3609e4eb-98ce-4f15-aead-bcd7844dad0e/gr1_lrg.jpg)
Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications - Cancer Treatment Reviews
![Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0ae1a419-8c04-4e6e-8a98-2b83b3eaa1d8/gr1.gif)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology
![Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial - The Lancet Oncology Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fed8c7ab-63f7-4478-bc18-ce99956742dd/gr1.gif)
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial - The Lancet Oncology
![Cureus | A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review Cureus | A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review](https://assets.cureus.com/uploads/figure/file/246471/lightbox_c1747cb0f40611ebb741a9a1e985fb6f-Add-a-little-bit-of-body-text-12.png)
Cureus | A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review
![Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/2/e001580/F1.large.jpg)
Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer
![Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5bce48f4-5d8b-4f4a-bcfb-b55f0b7a9a28/gr1_lrg.jpg)